Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$2.30
+15.6%
$2.10
$1.61
$11.20
$147.26M0.93779,582 shs2.34 million shs
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$0.55
-0.2%
$0.55
$0.22
$1.97
$30.32M1.031.75 million shs260 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$3.13
-0.6%
$3.71
$1.60
$10.48
$121.53M1.73770,713 shs150,078 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$1.81
+2.3%
$1.24
$0.78
$5.66
$128.80M0.731.34 million shs682,358 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+15.58%+19.17%-3.77%-24.09%-67.47%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
0.00%0.00%0.00%0.00%-64.34%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-0.63%-1.26%-7.94%-16.31%+7.56%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
+2.26%-0.55%+41.41%+14.56%-63.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
1.9049 of 5 stars
3.61.00.00.03.31.70.0
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.4621 of 5 stars
3.20.00.04.20.01.70.6
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.4269 of 5 stars
4.63.00.00.03.40.80.6
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3.1306 of 5 stars
3.43.00.00.04.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.10
Buy$20.43788.20% Upside
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.40
Hold$4.79771.56% Upside
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50554.95% Upside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.75
Moderate Buy$10.00452.49% Upside

Current Analyst Ratings Breakdown

Latest MRNS, TARA, VTYX, and LRMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00
3/14/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
3/11/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
3/6/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$1.86 per shareN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$30.99M0.98N/AN/A$0.31 per share1.77
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$6.01 per shareN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$40.42M-$1.72N/AN/AN/AN/A-55.96%-49.06%8/5/2025 (Estimated)
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$192.96M-$1.75N/AN/AN/AN/A-54.94%-50.01%8/14/2025 (Estimated)

Latest MRNS, TARA, VTYX, and LRMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
5/8/2025Q1 2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.48-$0.39+$0.09-$0.39N/AN/A
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
3/24/2025Q4 2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.29-$0.45-$0.16-$0.45N/AN/A
3/12/2025Q4 2024
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.57-$0.48+$0.09-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
13.10
13.10
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/A
1.66
1.47
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
9.85
9.85
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
23.52
23.52

Institutional Ownership

CompanyInstitutional Ownership
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
98.80%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.57 millionOptionable
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
11055.22 million52.20 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million18.05 millionOptionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.16 million57.86 millionOptionable

Recent News About These Companies

Ventyx Biosciences announces seven additional appointments to SAB
H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease

New MarketBeat Followers Over Time

Media Sentiment Over Time

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$2.30 +0.31 (+15.58%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.32 +0.02 (+0.87%)
As of 05/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Marinus Pharmaceuticals stock logo

Marinus Pharmaceuticals NASDAQ:MRNS

$0.55 0.00 (-0.16%)
As of 02/11/2025

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$3.13 -0.02 (-0.63%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$3.14 +0.00 (+0.16%)
As of 05/29/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

$1.81 +0.04 (+2.26%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.80 -0.01 (-0.50%)
As of 05/29/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.